​

Cullinan Therapeutics (CGEM) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CGEM Stock Forecast

Cullinan Therapeutics (CGEM) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $30.43, with a high of $38.00 and a low of $26.00. This represents a 118.14% increase from the last price of $13.95.

$10 $16 $22 $28 $34 $40 High: $38 Avg: $30.43 Low: $26 Last Closed Price: $13.95

CGEM Stock Rating

Cullinan Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

CGEM Price Target Upside V Benchmarks

TypeNameUpside
StockCullinan Therapeutics118.14%
SectorHealthcare Stocks 15.45%

Price Target Trends

1M3M12M
# Anlaysts147
Avg Price Target$28.00$28.75$30.43
Last Closing Price$13.95$13.95$13.95
Upside/Downside100.72%106.09%118.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26111---12
Feb, 26110---11
Jan, 2619---10
Dec, 2519---10
Nov, 2528---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 10, 2026Alex ThompsonStifel Nicolaus$28.00$15.1185.31%100.72%
Feb 02, 2026Guggenheim$30.00$11.96150.84%115.05%
Jan 08, 2026H.C. Wainwright$27.00$10.77150.70%93.55%
Jan 08, 2026Morgan Stanley$30.00$10.94174.22%115.05%
Dec 09, 2025Robert DriscollWedbush$34.00$12.18179.15%143.73%
Nov 24, 2025Julian HarrisonBTIG$38.00$11.90219.33%172.40%
Nov 20, 2025New Street$26.00$8.92191.48%86.38%
Oct 24, 2024David DaiUBS$30.00$15.6192.18%115.05%
Aug 08, 2024Jeffrey HungMorgan Stanley$38.00$16.38131.99%172.40%
May 16, 2024Edward WhiteH.C. Wainwright$28.00$26.724.79%100.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 17, 2026CitigroupBuyinitialise
Feb 02, 2026GuggenheimBuyinitialise
Jan 08, 2026H.C. WainwrightBuyBuyhold
Jan 08, 2026Morgan StanleyOverweightOverweighthold
Dec 17, 2025Cowen & Co.BuyBuyhold
Dec 09, 2025WedbushOutperformOutperformhold
Nov 24, 2025BTIGBuyBuyhold
Jan 29, 2025H.C. WainwrightBuyBuyhold
Oct 29, 2024BTIGBuyBuyhold
Oct 24, 2024UBSBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.48$-3.69$-3.11----
Avg Forecast$-1.28$-4.09$-3.04$-3.10$-3.00$-2.33$-2.87
High Forecast$-0.89$-4.05$-2.95$-2.51$-2.42$-0.05$-1.60
Low Forecast$-1.67$-4.13$-3.33$-4.09$-4.65$-4.12$-4.14
Surprise %15.63%-9.78%2.30%----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.94M------
Avg Forecast$18.91M-$1.67M$10.65M$33.02M$56.13M$58.02M
High Forecast$23.38M-$2.24M$14.28M$33.16M$56.64M$77.82M
Low Forecast$14.46M-$1.10M$7.02M$32.89M$55.62M$38.24M
Surprise %0.15%------

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.57M$-153.16M$-167.38M$-219.88M---
Avg Forecast$-53.08M$-169.76M$-130.49M$-137.20M$-146.98M$-86.74M$-119.11M
High Forecast$-36.82M$-168.11M$-122.60M$-104.43M$-100.70M$-2.28M$-66.31M
Low Forecast$-69.35M$-171.42M$-138.38M$-169.96M$-193.27M$-171.21M$-171.96M
Surprise %23.53%-9.78%28.28%60.27%---

CGEM Forecast FAQ

Is Cullinan Therapeutics stock a buy?

Cullinan Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cullinan Therapeutics is a favorable investment for most analysts.

What is Cullinan Therapeutics's price target?

Cullinan Therapeutics's price target, set by 8 Wall Street analysts, averages $30.43 over the next 12 months. The price target range spans from $26 at the low end to $38 at the high end, suggesting a potential 118.14% change from the previous closing price of $13.95.

How does Cullinan Therapeutics stock forecast compare to its benchmarks?

Cullinan Therapeutics's stock forecast shows a 118.14% upside, outperforming the average forecast for the healthcare stocks sector (15.45%).

What is the breakdown of analyst ratings for Cullinan Therapeutics over the past three months?

  • March 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cullinan Therapeutics’s EPS forecast?

Cullinan Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-2.33 in 2027, and $-2.87 in 2028.

What is Cullinan Therapeutics’s revenue forecast?

Cullinan Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $33.02M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $56.13M, and $58.02M for 2028.

What is Cullinan Therapeutics’s net income forecast?

Cullinan Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-147M, representing a -33.15% decrease from the reported $-220M in 2025. Projections indicate $-86.744M in 2027, and $-119M in 2028.